1991
DOI: 10.1016/s0090-1229(06)80011-5
|View full text |Cite
|
Sign up to set email alerts
|

Therapeutic effects of leflunomide, a new antirheumatic drug, on glomerulonephritis induced by the antibasement membrane antibody in rats

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
8
0

Year Published

1995
1995
2014
2014

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 32 publications
(8 citation statements)
references
References 13 publications
0
8
0
Order By: Relevance
“…These effects correlate with the suppression of autoantibodies to tubular basement membrane [50]. In glomerulonephritis induced by rabbit antiserum against rat glomerular basement membrane, leflunomide demonstrates preventive and therapeutic effects, reducing urinary total protein, plasma total cholesterol and fibrinogen, thymus weight and deposition of fibrin, C3, and IgG in the glomerulus [51]. In a model of experimental autoimmune uveitis induced by injection of retinal S-antigen into the foot-pad of Lewis rats, leflunomide, administered either orally or topically, suppressed the ocular disease signs and symptoms and retinal necrosis, reducing the S-antigen antibody levels associated with experimental autoimmune uveitis in a dose-dependent manner [52].…”
Section: Autoimmune Diseasementioning
confidence: 88%
See 1 more Smart Citation
“…These effects correlate with the suppression of autoantibodies to tubular basement membrane [50]. In glomerulonephritis induced by rabbit antiserum against rat glomerular basement membrane, leflunomide demonstrates preventive and therapeutic effects, reducing urinary total protein, plasma total cholesterol and fibrinogen, thymus weight and deposition of fibrin, C3, and IgG in the glomerulus [51]. In a model of experimental autoimmune uveitis induced by injection of retinal S-antigen into the foot-pad of Lewis rats, leflunomide, administered either orally or topically, suppressed the ocular disease signs and symptoms and retinal necrosis, reducing the S-antigen antibody levels associated with experimental autoimmune uveitis in a dose-dependent manner [52].…”
Section: Autoimmune Diseasementioning
confidence: 88%
“…A77 1726 suppresses autoimmune diseases in many animal models [45][46][47][48][49][50][51][52], and also decreases autoantibody production in these models. Both allo-and xenoantibody levels are also decreased in leflunomide-treated rodent recipients of allo-and xenografts [24,[53][54][55][56], but the mechanisms of action of the drug on B-cell proliferation and on antibody production are unknown.…”
Section: In Vivomentioning
confidence: 99%
“…However, nephrotic syndrome reappeared in five out of the 23 patients (21.7%) who were in remission by 15 months. Median time to relapse was 14 months (range, [8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27] after cessation of LEF. There were no significant differences in either biochemical or demographic parameters at baseline between relapsing and non-relapsing patients.…”
Section: Relapse and Renal Functionmentioning
confidence: 99%
“…Since it was introduced in 1998, LEF has been also explored for treatment of glomerulonephritis. Ogawa et al 16 used LEF to treat anti-glomerular basement membrane glomerulonephritis in animal models. They reported that LEF had therapeutic effects on proteinuria as well as inhibitory effects on the glomerular immunoglobulin G and C3 deposits.…”
Section: Introductionmentioning
confidence: 99%
“…Leflunomide was given orally by a gastric tube at a dose of 2 mg/kg body weight suspended in 1 ml of distilled water daily for 8 weeks. The dose was equivalent to human therapeutic dose [21,22].…”
Section: Test Drug and Treatmentmentioning
confidence: 99%